Estimating Survival in Patients with Skeletal Metastases Using PATHFx: An Adaptive, Validated, Clinical Decision Support Tool
We are in the middle of a healthcare revolution. Big data including demographics, molecular markers, and physiologic indicators are being codified by advanced techniques in information technology. The result is an explosion in the number of prognostic models that have been applied to a variety of clinical problems. Given that mobile or otherwise interconnected applications are ubiquitous in modern society, physicians may be tempted to confuse fingertip availability and relative ease of use with a tool that has been properly vetted for clinical use. It would seem that tech-savvy doctors are abandoning their healthy skepticism that has been ingrained by years of journal clubs, academic medicine, and/or clinical practice. However, this should not be the case. When using an “app,” physicians should demand the same level of scrutiny and apply the same healthy skepticism as they do for the literature they read, the implants they select, and the medications they prescribe .
- 1.Forsberg JA. Suggested guidelines. In: Wedin R, Bauer H, Weidenhielm L, editors. Turning data into decisions. Stockholm: Karolinska University Press; 2015. p. 1–74.Google Scholar
- 20.Karnofsky DA. The clinical evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press; 1949.Google Scholar
- 31.Piccioli A, Spinelli MS, Forsberg JA, et al. How do we estimate survival? External validation of a tool for survival estimation in patients with metastatic bone disease-decision analysis and comparison of three international patient populations. BMC Cancer. 2015;15(1):424. https://doi.org/10.1186/s12885-015-1396-5.CrossRefPubMedPubMedCentralGoogle Scholar